Tonix Pharmaceuticals Holding Corp. (TNXP)

2.31 -0.03 (-1.282%)

IEX Real-Time Price

April 23, 2019 EST.

NASDAQ Global Market : Healthcare

Prev Close 2.34

Price Open 2.32

Volume: 732,032

Avg Volume: 1.18M

Market Cap: 14.07M

P/E Ratio -0.08

52 Wk Range 1.7-51.1



TNXP Short Interest Statistics


Report Date
Float Share
Short Interest
Short Ratio
Short % to Float

2018-10-15
6.07M
1.17M
1.23
19.25%

2018-09-28
6.07M
581,273
1.99
9.58%

2018-09-14
6.07M
471,753
0.41
7.77%

2018-08-31
6.07M
514,775
0.47
8.48%




TNXP Earning Report


Report Date
Fiscal Period
Announce Time
Estimated EPS(#)
Actual EPS
Surprise Dollar

2019-03-18
Q4 2018
N/A
-3.87 (2)
0.00
0.00

2018-11-09
Q3 2018
N/A
-6.50 (5)
-5.70
0.80

2018-11-06
Q3 2018
N/A
-0.65 (5)
0.00
0.00

2018-08-13
Q2 2018
N/A
-0.76 (5)
-0.73
0.03

News

Tonix Pharma +8% after FDA withdraws rescind letter for Tonmya (2019-04-22 07:49 SeekingAlpha)

Tonix Pharmaceuticals (NASDAQ: TNXP ) announces that the FDA has withdrawn its Breakthrough Therapy Designation Rescind letter issued on December 20, 2018 and confirmed that Tonmya (cyclobenzaprine HCl sublingual tablets) remains in effect as Breakthrough Therapy for the treatment of postt…

 


Statistics

Shares Outstanding: 6.09M

Top 15 Institution Percent: 9.80

Price To Sales: N/A

Price To Book: 0.61

Revenue: N/A

Gross Profit: N/A

Cash: N/A

Debt: N/A

Return On Assets: -113.06

Return On Equity: -124.31

Profit Margin: N/A

Price History

Beta: 1.89

50-day Moving Avg: 2.35

200-day Moving Avg: 8.02

YTD Change: 3.12

5-day Change: -4.94

1-month Change: -1.70

3-month Change: 21.58

6-month Change: -64.99

1-year Change: -92.71

Revenue Per Share: 0.00

Revenue Per Employee: 0.00



Dividend

Dividend Yield: -

EX-Dividend Date: -

Dividend Rate: -


Company Profile

Name: Tonix Pharmaceuticals Holding Corp.

Exchange: NASDAQ Global Market

Industry: Biotechnology

Sector: Healthcare

Website: http://www.tonixpharma.com

Tonix Pharmaceuticals Holding Corp is a clinical-stage pharmaceutical company dedicated to the development of pharmaceutical products to address public health challenges. Its drug development program is focused on delivering treatment for PTSD.